The nation of Zimbabwe has rejected a substantial American healthcare agreement valued at $367m (£272m) over five years because of the United States' request for sensitive information.
This move was revealed after a internal memorandum from December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the deal was "unbalanced".
A government spokesman has since clarified that the United States was requesting genetic material for scientific study and commercial gain while refused to share the benefits from any future vaccines.
"We are forced to start the difficult and regrettable process of scaling back our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had furnished more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for continued talks to find a deal acceptable to all parties so the country's vital HIV programme can continue.
Wider Background
Zimbabwe's decision comes after a comparable case in Kenya, where a court suspended a similar deal with the US following concerns were filed about the safety of citizens' health data.
After resuming the presidency last year, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
The agency had managed assistance for the American government, but Trump claimed its expenditure was "wasteful" and his administration was seeking government-to-government deals to boost transparency and accountability.
As per reports, 16 African countries have to date agreed to these new agreements, constituting more than $18.3bn of fresh investment.
Details of the Rejected Deal
The money for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership might have yielded significant benefits for the people of Zimbabwe, particularly the 1.2 million currently receiving antiretroviral therapy via American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to surrender its genetic material and health information over an extended period, with no corresponding assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that provided information," he stated.
"Effectively, our country would provide the raw materials for medical research with no assurance that the end products would be available to our citizens should a future pandemic emerge."
Sovereignty and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending systems already set up via the international health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme created to manage potential pandemics.
"This framework is intended to guarantee that when a country provides its data, the benefits – including vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as hostility towards the US," he added.
"We welcome continued dialogue with our American counterparts on how subsequent collaboration could be designed in a way that honours the independence and dignity of both nations."
Health Experts Reaction
A leading public health body stated it understood the government's concerns, but recommended that talks must proceed since a large portion of the nation's Aids initiatives relied on international support.
"In cases where specific concerns exist, such as those relating to information security or agreement terms, these can frequently be resolved through detailed discussion and negotiated safeguards," it said.
The halted deal underscores the complex challenges between receiving vital international aid and protecting a country's data in an increasingly interconnected world.